Related Experiment Video
Updated: Jun 20, 2025

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers
Published on: September 20, 2018
Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance
Zhiquan Wang1, Rentian Wu1, Qian Nie1
1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
The long-term effectiveness of targeted cancer therapies is limited by the development of resistance. Although epigenetic reprogramming has been implicated in resistance, the mechanisms remain elusive. Herein, we demonstrate that increased chromatin accessibility is involved in adaptive BRAF inhibitor (BRAFi)-resistance in melanoma cells. We observed loss of chromatin assembly factor 1 (CAF-1) and its related histone H3 lysine 9 trimethylation (H3K9me3) with adaptive BRAFi resistance. We further showed that depletion of CAF-1 provides chromatin plasticity for effective reprogramming by AP1 components to promote BRAFi resistance. Our data suggest that therapeutic approaches to restore H3K9me3 levels may compensate for the loss of CAF-1 and, in turn, suppress resistance to BRAF inhibitors.
Insights
Targeted cancer therapy resistance in melanoma involves epigenetic changes. Restoring histone H3 lysine 9 trimethylation (H3K9me3) may overcome resistance to BRAF inhibitors by targeting chromatin assembly factor 1 (CAF-1).
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Targeted cancer therapies, like BRAF inhibitors (BRAFi), face challenges due to acquired resistance.
- Epigenetic reprogramming is implicated in resistance, but the underlying mechanisms are not fully understood.
Purpose of the Study:
- To investigate the role of epigenetic modifications in adaptive BRAF inhibitor resistance in melanoma.
- To identify specific molecular mechanisms contributing to BRAFi resistance.
Main Methods:
- Analysis of chromatin accessibility changes in melanoma cells developing adaptive BRAFi resistance.
- Assessment of chromatin assembly factor 1 (CAF-1) and histone H3 lysine 9 trimethylation (H3K9me3) levels.
- Investigating the impact of CAF-1 depletion on chromatin plasticity and AP1 component reprogramming.
Main Results:
- Increased chromatin accessibility was observed in adaptive BRAFi-resistant melanoma cells.
- Loss of CAF-1 and associated H3K9me3 marks correlated with acquired BRAFi resistance.
- CAF-1 depletion facilitated chromatin plasticity, enabling AP1 component reprogramming and promoting BRAFi resistance.
Conclusions:
- Adaptive BRAF inhibitor resistance in melanoma is linked to increased chromatin accessibility and loss of CAF-1/H3K9me3.
- Therapeutic strategies aimed at restoring H3K9me3 levels could potentially overcome CAF-1 loss and suppress BRAFi resistance.
Related Concept Videos
Spreading of Chromatin Modifications
Writers
The writer...
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Epigenetic Regulation
X-chromosome...
Methods of Nuclear Reprogramming
Nucleosome Remodeling
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
Inheritance of Chromatin Structures

